Luca Mignani
Overview
Explore the profile of Luca Mignani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pelisenco I, Zizioli D, Guerra F, Grossi I, Bucci C, Mignani L, et al.
Cell Commun Signal
. 2024 Nov;
22(1):552.
PMID: 39558342
Background: Extracellular vesicles (EVs) are a group of nanoscale cell-derived membranous structures secreted by all cell types, containing molecular cargoes involved in intercellular communication. EVs can be used to mimic...
2.
Zizioli D, Quiros-Roldan E, Ferretti S, Mignani L, Tiecco G, Monti E, et al.
Int J Mol Sci
. 2024 May;
25(9).
PMID: 38731859
Dolutegravir (DTG) is one of the most prescribed antiretroviral drugs for treating people with HIV infection, including women of child-bearing potential or pregnant. Nonetheless, neuropsychiatric symptoms are frequently reported. Early...
3.
Impact of an irreversible β-galactosylceramidase inhibitor on the lipid profile of zebrafish embryos
Guerra J, Belleri M, Paiardi G, Tobia C, Capoferri D, Corli M, et al.
Comput Struct Biotechnol J
. 2024 Apr;
23:1397-1407.
PMID: 38596316
Krabbe disease is a sphingolipidosis characterized by the genetic deficiency of the acid hydrolase β-galactosylceramidase (GALC). Most of the studies concerning the biological role of GALC performed on Krabbe patients...
4.
Capoferri D, Mignani L, Manfredi M, Presta M
Int J Mol Sci
. 2024 Mar;
25(5).
PMID: 38474307
Mitochondrial plasticity, marked by a dynamism between glycolysis and oxidative phosphorylation due to adaptation to genetic and microenvironmental alterations, represents a characteristic feature of melanoma progression. Sphingolipids play a significant...
5.
Zizioli D, Ferretti S, Tiecco G, Mignani L, Monti E, Castelli F, et al.
Int J Mol Sci
. 2023 Jul;
24(14).
PMID: 37511423
In the past, one of the most widely used non-nucleoside reverse transcriptase inhibitors (NNRTI) in first-line antiretroviral therapy (ART) of HIV infection was efavirenz (EFV), which is already used as...
6.
Capoferri D, Chiodelli P, Corli M, Belleri M, Scalvini E, Mignani L, et al.
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37445731
β-Galactosylceramidase (GALC) is a lysosomal enzyme involved in sphingolipid metabolism by removing β-galactosyl moieties from β-galactosylceramide and β-galactosylsphingosine. Previous observations have shown that GALC may exert pro-oncogenic functions in melanoma...
7.
Mignani L, Facchinello N, Varinelli M, Massardi E, Tiso N, Ravelli C, et al.
Int J Mol Sci
. 2023 Apr;
24(8).
PMID: 37108275
In vertebrates, two homologous heterotetrameric AP1 complexes regulate the intracellular protein sorting via vesicles. AP-1 complexes are ubiquitously expressed and are composed of four different subunits: γ, β1, μ1 and...
8.
Mignani L, Guerra J, Corli M, Capoferri D, Presta M
Int J Mol Sci
. 2023 Mar;
24(5).
PMID: 36902174
Sphingolipidoses are inborn errors of metabolism due to the pathogenic mutation of genes that encode for lysosomal enzymes, transporters, or enzyme cofactors that participate in the sphingolipid catabolism. They represent...
9.
Zizioli D, Zanella I, Mignani L, Degli Antoni M, Castelli F, Quiros-Roldan E
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36768311
As most new medications, Cabotegravir (CAB) was recently approved as an antiretroviral treatment of HIV infection without in-depth safety information on in utero exposure. Although no developmental toxicity in rats...
10.
Zizioli D, Ferretti S, Mignani L, Castelli F, Tiecco G, Zanella I, et al.
Birth Defects Res
. 2022 Nov;
115(4):430-440.
PMID: 36373861
Background: Nirmatrelvir, in combination with ritonavir, is one of the first orally available antiviral treatment for coronavirus disease 2019 (COVID-19). Symptomatic pregnant women are at increased risk for severe illness...